The human papillomavirus vaccine market size is anticipated to reach US$ 3.8 Bn by 2026, expanding at a CAGR of over 5.7% from 2019 to 2026.
The report analyzes and forecasts the human papillomavirus vaccine market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of human papillomavirus vaccine, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major human papillomavirus vaccine companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of human papillomavirus vaccine upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of human papillomavirus vaccine and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global human papillomavirus vaccine market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the human papillomavirus vaccine market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of human papillomavirus vaccine market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles major players operating in the global human papillomavirus vaccine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Merck & Co., Inc., GlaxoSmithKline plc. Sanofi, Johnson & Johnson, AstraZeneca, and Serum Institute of India Pvt. Ltd.
The global human papillomavirus vaccine market has been segmented as below:
Global Human Papillomavirus Vaccine Market, by Valence
Global Human Papillomavirus Vaccine Market, by Indication
Global Human Papillomavirus Vaccine Market, by Distribution Channel
Global Human Papillomavirus Vaccine Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights
2. Assumptions and Acronyms Used
3. Research Approach & Methodology
3.1. Research Methodology Overview
3.2. Project Initiation
3.3. Secondary Research Methodology
3.4. Primary Research Methodology
3.5. Analysis Research Methodology
3.6. Final Report & Conclusions Research Methodology
4. Executive Summary: Global Human Papillomavirus Vaccine Market
5. Market Overview
5.1. Overview
5.2. Key Industry Events and Developments
5.3. Global Human Papillomavirus Vaccine Market Forecast and Analysis
5.4. Global Human Papillomavirus Vaccine Market Outlook
6. Market Dynamics
6.1. Drivers and Restraints Snapshot Analysis
6.2. Drivers
6.3. Restraints
6.4. Opportunity
6.5. Key Trends
6.6. Institutional Sales Overview, by Volume (No. of Unit Dose)
6.7. Pricing Analysis
6.8. Pipeline Analysis: Human Papillomavirus Vaccine
7. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Valence
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast by Valence, 2017–2026
7.3.1. Bivalent
7.3.2. Quadrivalent, and Nonavalent
7.4. Global Human Papillomavirus Vaccines Market Analysis, by Valence
7.5. Global Human Papillomavirus Vaccines Market Forecast, by Valence
7.6. Global Human Papillomavirus Vaccines Market Analysis, by Valence
8. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast by Indication, 2017–2026
8.3.1. Cervical Cancer
8.3.2. Anal Cancer
8.3.3. Vaginal Cancer
8.3.4. Penile Cancer
8.3.5. Vulvar Cancer
8.3.6. Oropharyngeal Cancer
8.3.7. Genital Warts
8.3.8. Others
8.4. Global Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
8.5. Global Human Papillomavirus Vaccines Market Forecast, by Indication
8.6. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Indication
9. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast by Distribution Channel, 2017–2026
9.3.1. Physicians
9.3.2. Wholesalers
9.3.3. Physician Distributors
9.3.4. Government Entities
9.3.5. Public and Private Alliances
9.4. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
9.5. Global Human Papillomavirus Vaccines Market Forecast, by Distribution Channel
9.6. Global Human Papillomavirus Vaccines Market Analysis, by Distribution Channel
10. Global Human Papillomavirus Vaccine Market Analysis and Forecasts, by Region
10.1. Global Human papillomavirus vaccine Market Snapshot, by Country
10.2. Global Human Papillomavirus Vaccines Market Analysis, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Human Papillomavirus Vaccines Market Forecast, by Region
10.4. Global Human Papillomavirus Vaccines Market Attractiveness Analysis, by Region
11. North America Human Papillomavirus Vaccine Market Analysis
11.1. Policies and Regulations
11.2. Key Findings
11.3. North America Human Papillomavirus Vaccines Market Overview
11.4. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
11.4.1. U.S.
11.4.2. Canada
11.5. Market Attractiveness Analysis
11.6. North America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
11.6.1. Bivalent
11.6.2. Quadrivalent, and Nonavalent
11.7. Market Attractiveness Analysis
11.8. North America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
11.8.1. Cervical Cancer
11.8.2. Anal Cancer
11.8.3. Vaginal Cancer
11.8.4. Penile Cancer
11.8.5. Vulvar Cancer
11.8.6. Oropharyngeal Cancer
11.8.7. Genital Warts
11.8.8. Others
11.9. Market Attractiveness Analysis
11.10. Market Value Share Analysis by Distribution Channel, 2017–2026
11.10.1. Physicians
11.10.2. Wholesalers
11.10.3. Physician Distributors
11.10.4. Government Entities
11.10.5. Public and Private Alliances
12. Europe Human Papillomavirus Vaccine Market Analysis
12.1. Policies and Regulations
12.2. Key Findings
12.3. Europe Human Papillomavirus Vaccines Market Overview
12.4. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
12.4.1. Germany
12.4.2. France
12.4.3. Italy
12.4.4. Spain
12.4.5. U.K.
12.4.6. Rest of Europe
12.5. Market Attractiveness Analysis
12.6. Europe Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
12.6.1. Bivalent
12.6.2. Quadrivalent, and Nonavalent
12.7. Market Attractiveness Analysis
12.8. Europe Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
12.8.1. Cervical Cancer
12.8.2. Anal Cancer
12.8.3. Vaginal Cancer
12.8.4. Penile Cancer
12.8.5. Vulvar Cancer
12.8.6. Oropharyngeal Cancer
12.8.7. Genital Warts
12.8.8. Others
12.9. Market Attractiveness Analysis
12.10. Market Value Share Analysis by Distribution Channel, 2017–2026
12.10.1. Physicians
12.10.2. Wholesalers
12.10.3. Physician Distributors
12.10.4. Government Entities
12.10.5. Public and Private Alliances
13. Asia Pacific Human Papillomavirus Vaccine Market Analysis
13.1. Policies and Regulations
13.2. Key Findings
13.3. Asia Pacific Human Papillomavirus Vaccines Market Overview
13.4. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. Rest of Asia Pacific
13.5. Market Attractiveness Analysis
13.6. Asia Pacific Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
13.6.1. Bivalent
13.6.2. Quadrivalent, and Nonavalent
13.7. Market Attractiveness Analysis
13.8. Asia Pacific Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
13.8.1. Cervical Cancer
13.8.2. Anal Cancer
13.8.3. Vaginal Cancer
13.8.4. Penile Cancer
13.8.5. Vulvar Cancer
13.8.6. Oropharyngeal Cancer
13.8.7. Genital Warts
13.8.8. Others
13.9. Market Attractiveness Analysis
13.10. Market Value Share Analysis by Distribution Channel, 2017–2026
13.10.1. Physicians
13.10.2. Wholesalers
13.10.3. Physician Distributors
13.10.4. Government Entities
13.10.5. Public and Private Alliances
14. Latin America Human Papillomavirus Vaccine Market Analysis
14.1. Policies and Regulations
14.2. Key Findings
14.3. Latin America Human Papillomavirus Vaccines Market Overview
14.4. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Attractiveness Analysis
14.6. Latin America Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
14.6.1. Bivalent
14.6.2. Quadrivalent, and Nonavalent
14.7. Market Attractiveness Analysis
14.8. Latin America Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
14.8.1. Cervical Cancer
14.8.2. Anal Cancer
14.8.3. Vaginal Cancer
14.8.4. Penile Cancer
14.8.5. Vulvar Cancer
14.8.6. Oropharyngeal Cancer
14.8.7. Genital Warts
14.8.8. Others
14.9. Market Attractiveness Analysis
14.10. Market Value Share Analysis by Distribution Channel, 2017–2026
14.10.1. Physicians
14.10.2. Wholesalers
14.10.3. Physician Distributors
14.10.4. Government Entities
14.10.5. Public and Private Alliances
15. Middle East & Africa Human Papillomavirus Vaccine Market Analysis
15.1. Policies and Regulations
15.2. Key Findings
15.3. Middle East & Africa Human Papillomavirus Vaccines Market Overview
15.4. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Country
15.4.1. GCC Countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Market Attractiveness Analysis
15.6. Middle East & Africa Human Papillomavirus Vaccines Market Value Share and Attractiveness Analysis, by Valance
15.6.1. Bivalent
15.6.2. Quadrivalent, and Nonavalent
15.7. Market Attractiveness Analysis
15.8. Middle East & Africa Human Papillomavirus Vaccines Market Value Share Analysis, by Indication
15.8.1. Cervical Cancer
15.8.2. Anal Cancer
15.8.3. Vaginal Cancer
15.8.4. Penile Cancer
15.8.5. Vulvar Cancer
15.8.6. Oropharyngeal Cancer
15.8.7. Genital Warts
15.8.8. Others
15.9. Market Attractiveness Analysis
15.10. Market Value Share Analysis by Distribution Channel, 2017–2026
15.10.1. Physicians
15.10.2. Wholesalers
15.10.3. Physician Distributors
15.10.4. Government Entities
15.10.5. Public and Private Alliances
16. Competition Landscape
16.1. Human Papillomavirus (HPV) Vaccine Sales Analysis
16.2. Competition Matrix
16.3. Human Papillomavirus (HPV) Vaccine Market Share Analysis, by Company
16.4. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.4.1. Merck & Co., Inc.
16.4.1.1. Company Description
16.4.1.2. Financial Overview
16.4.1.3. Strategic Overview
16.4.1.4. Recent Developments
16.4.1.5. SWOT ANALYSIS
16.4.2. GlaxoSmithKline plc.
16.4.2.1. Company Description
16.4.2.2. Financial Overview
16.4.2.3. Strategic Overview
16.4.2.4. Recent Developments
16.4.2.5. SWOT ANALYSIS
16.4.3. Sanofi
16.4.3.1. Company Description
16.4.3.2. Financial Overview
16.4.3.3. Strategic Overview
16.4.3.4. SWOT ANALYSIS
16.4.4. Johnson & Johnson
16.4.4.1. Company Description
16.4.4.2. Financial Overview
16.4.4.3. Recent Developments
16.4.4.4. SWOT ANALYSIS
16.4.5. AstraZeneca
16.4.5.1. Company Description
16.4.5.2. Financial Overview
16.4.5.3. Recent Developments
16.4.5.4. SWOT ANALYSIS
16.4.6. Serum Institute of India Pvt. Ltd.
16.4.6.1. Company Description
16.4.6.2. Recent Developments
16.4.6.3. SWOT ANALYSIS
16.4.7. Xiamen Innovax Biotech CO., LTD. (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)
16.4.7.1. Company Description
16.4.7.2. SWOT ANALYSIS
16.4.8. General Incorporated Foundation, The Chemo- Sero-Therapeutic Research Institute (Kaketsuken)
16.4.8.1. Company Description
16.4.8.2. Recent Developments
16.4.8.3. SWOT ANALYSIS
16.4.9. Bharat Biotech
16.4.9.1. Company Description
16.4.9.2. SWOT ANALYSIS
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers